EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

The Efficacy of Targeted Monoclonal IgA Antibodies Against Pancreatic Ductal Adenocarcinoma

Léon Raymakers iD, Elsemieke M Passchier, Meggy E L Verdonschot iD, Mitchell Evers, Chilam Chan iD, Karel C Kuijpers, G Mihaela Raicu, I Quintus Molenaar, Hjalmar C van Santvoort, Karin Strijbis iD, Martijn P W Intven, Lois A Daamen iD und 2 weitere

Cells · 24.04.2025 · 14 (9) · 632

DOI: 10.3390/cells14090632 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cells, online erschienen am 24.04.2025. Verfasst von Léon Raymakers und 13 weiteren Autor:innen. Beteiligte Einrichtung: Center for Translational Immunology, University Medical Center Utrecht, Heidelberglaan 100, 3584 CX Utrecht, The Netherlands. Hauptthemen laut MEDLINE: Carcinoma, Pancreatic Ductal, Pancreatic Neoplasms, Antibodies, Monoclonal, Immunoglobulin A. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 95 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Health Holland, Dutch Cancer Society.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The efficacy of immunotherapy in pancreatic ductal adenocarcinoma (PDAC) remains limited. The tumor microenvironment (TME), characterized by the accumulation of suppressive myeloid cells including neutrophils, attributes to immunotherapy resistance in PDAC. IgA monoclonal antibodies (mAbs) can activate neutrophils to kill tumor cells; this can be further enhanced by blocking the myeloid immune checkpoint CD47. In this study, we investigated the potential of this therapeutic strategy for PDAC. We determined the expression of tumor-associated antigens (TAAs) on PDAC cell lines and fresh patient samples, and the results showed that the TAAs epithelial cell adhesion molecule (EpCAM), trophoblast cell surface antigen 2 (TROP2) and mucin-1 (MUC1), as well as CD47 were consistently expressed on PDAC. In line with this, we showed that IgA mAbs against EpCAM can activate neutrophils to lyse various PDAC cell lines and tumor cells, which can be augmented by addition of CD47 blockade. In addition, we observed that neutrophils were present in patient tumors and expressed the receptor for IgA. In conclusion, our results indicate that a combination of IgA mAb with CD47 blockade is a promising preclinical treatment strategy for PDAC, which merits further investigation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Pancreatic DuctalPancreatic NeoplasmsAntibodies, MonoclonalImmunoglobulin AHumansCell Line, TumorNeutrophilsAntigens, NeoplasmTumor MicroenvironmentEpithelial Cell Adhesion MoleculeCD47 AntigenImmunotherapyMucin-1

Stichwörter der Autor:innen

IgAPDACPMNsmAbsmonoclonal antibodiesneutrophilspancreatic cancerpancreatic ductal adenocarcinomapolymorphonuclear cells

Substanzen

Antibodies, MonoclonalImmunoglobulin AAntigens, NeoplasmEpithelial Cell Adhesion MoleculeCD47 AntigenMucin-1

Autor:innen und Institutionen

  • Center for Translational Immunology, University Medical Center Utrecht, Heidelberglaan 100, 3584 CX Utrecht, The Netherlands.
  • Division of Imaging & Oncology, University Medical Center Utrecht Cancer Center, Heidelberglaan 100, 3584 CX Utrecht, The Netherlands.
  • Department of Pathology, Regional Academic Cancer Center Utrecht, UMC Utrecht Cancer Center & St. Antonius Hospital Nieuwegein, St. Antonius Hospital Nieuwegein, Koekoekslaan 1, 3435 CM Nieuwegein, The Netherlands.
  • Department of Surgery, Regional Academic Cancer Center Utrecht, UMC Utrecht Cancer Center & St. Antonius Hospital Nieuwegein, Utrecht University, Heidelberglaan 100, 3584 CX Utrecht, The Netherlands.
  • Department of Biomolecular Health Sciences, Division Infectious Diseases and Immunology, Faculty of Veterinary Medicine, Utrecht University, Yalelaan 1, 3584 CL Utrecht, The Netherlands.

ORCID-Profile: Léon Raymakers, Meggy E L Verdonschot, Chilam Chan, Karin Strijbis, Lois A Daamen, Patricia A Olofsen

Förderung

  • Health Holland
  • Dutch Cancer Society

Zitieren

APA

Raymakers, L., Passchier, E. M., Verdonschot, M. E. L., Evers, M., Chan, C., Kuijpers, K. C., Raicu, G. M., Molenaar, I. Q., van Santvoort, H. C., Strijbis, K., Intven, M. P. W., Daamen, L. A., Leusen, J. H. W., & Olofsen, P. A. (2025). The Efficacy of Targeted Monoclonal IgA Antibodies Against Pancreatic Ductal Adenocarcinoma. Cells, 14(9), 632. https://doi.org/10.3390/cells14090632

Vancouver

Raymakers L, Passchier EM, Verdonschot MEL, Evers M, Chan C, Kuijpers KC, et al. The Efficacy of Targeted Monoclonal IgA Antibodies Against Pancreatic Ductal Adenocarcinoma. Cells. 2025;14(9):632. doi:10.3390/cells14090632

BibTeX
@article{Raymakers2025,
  author = {Raymakers, Léon and Passchier, Elsemieke M and Verdonschot, Meggy E L and Evers, Mitchell and Chan, Chilam and Kuijpers, Karel C and Raicu, G Mihaela and Molenaar, I Quintus and van Santvoort, Hjalmar C and Strijbis, Karin and Intven, Martijn P W and Daamen, Lois A and Leusen, Jeanette H W and Olofsen, Patricia A},
  title = {The Efficacy of Targeted Monoclonal IgA Antibodies Against Pancreatic Ductal Adenocarcinoma},
  journal = {Cells},
  year = {2025},
  volume = {14},
  number = {9},
  pages = {632},
  doi = {10.3390/cells14090632}
}
Kostenlos starten →